表紙
市場調査レポート

脳腫瘍:パイプライン製品の分析

Brain Tumor - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 213057
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
脳腫瘍:パイプライン製品の分析 Brain Tumor - Pipeline Review, H2 2014
出版日: 2014年07月15日 ページ情報: 英文 90 Pages
概要

脳腫瘍は、脳内の細胞の異常増殖で、癌性または非癌性(良性)腫瘍があります。脳腫瘍の症状は、腫瘍の大きさ、種類、場所によって異なります。最もよく見られる症状は、頭痛(朝になると悪化)、言語・視覚・聴覚の変化、平衡度・歩行の問題、気分・性格・集中力の変化、筋肉の引きつり・痙攣(発作)、腕や脚のしびれ・うずきなどです。治療には、外科手術、放射線療法、化学療法などが含まれます。

当レポートでは、脳腫瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

脳腫瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Chong Kun Dang Pharmaceutical Corp
  • Pfizer Inc.
  • Bayer AG
  • Nanobiotix
  • Hutchison MediPharma Limited
  • Siena Biotech S.p.A
  • Oncovir, Inc.
  • DEKK-TEC, Inc.
  • SignPath Pharma Inc
  • CalAsia Pharmaceuticals, Inc.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • DM-CHOC-PEN
  • Beloranib
  • Poly-ICLC
  • GliAtak
  • indoximod
  • dianhydrogalactitol
  • HMPL-813
  • DC/AAT + DC/AAT-Flu + DC/KLH
  • Dendritic Cell Vaccine
  • CIGB-128
  • Cell Therapy for Brain Cancer
  • HOOI
  • Tankyrase/Wnt Inhibitors
  • Bispecific T-Cell Engager
  • Bay-846
  • NBTX-TOPO
  • VO-100
  • PF-06463922
  • Small Molecule To Inhibit Hsp90 Alpha and TRAP1 For Brain Cancer
  • Polymeric Nanocurcumin
  • Monoclonal Antibody to Inhibit EGFR for Brain Tumor

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5238IDB

Summary

Global Markets Direct's, 'Brain Tumor - Pipeline Review, H2 2014', provides an overview of the Brain Tumor's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Brain Tumor
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain Tumor and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Tumor pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Tumor
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Tumor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Brain Tumor Overview
  • Therapeutics Development
    • Pipeline Products for Brain Tumor - Overview
    • Pipeline Products for Brain Tumor - Comparative Analysis
  • Brain Tumor - Therapeutics under Development by Companies
  • Brain Tumor - Therapeutics under Investigation by Universities/Institutes
  • Brain Tumor - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Brain Tumor - Products under Development by Companies
  • Brain Tumor - Products under Investigation by Universities/Institutes
  • Brain Tumor - Companies Involved in Therapeutics Development
    • Chong Kun Dang Pharmaceutical Corp.
    • Pfizer Inc.
    • Bayer AG
    • Nanobiotix
    • Hutchison MediPharma Limited
    • Siena Biotech S.p.A.
    • Oncovir, Inc.
    • DEKK-TEC, Inc.
    • SignPath Pharma Inc
    • CalAsia Pharmaceuticals, Inc.
  • Brain Tumor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • DM-CHOC-PEN - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • beloranib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Poly-ICLC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GliAtak - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HMPL-813 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Brain Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HOOI - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Tankyrase/Wnt Inhibitors - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bispecific Antibody for Brain Tumor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bay-846 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NBTX-TOPO - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VO-100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06463922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 Alpha and TRAP1 for Brain Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Polymeric Nanocurcumin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit EGFR for Brain Tumor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Brain Tumor - Recent Pipeline Updates
  • Brain Tumor - Dormant Projects
  • Brain Tumor - Discontinued Products
  • Brain Tumor - Product Development Milestones
    • Featured News & Press Releases
      • May 20, 2014: Oncolytics Biotech Collaborators to Present Positive Brain Cancer Clinical Trial Data at the 50th Annual ASCO Meeting
      • Dec 16, 2013: Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors
      • Nov 16, 2013: Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress
      • Mar 18, 2013: Anti-nausea Drug Halts Growth Of Brain Tumors, Research Finds
      • Dec 17, 2012: new immune therapy successfully treats brain tumors in mice
      • Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors
      • Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors
      • Feb 02, 2011: Antisense Pharma Receives Approval For Clinical Studies In South Korea And Taiwan In Malignant Brain Tumors
      • Nov 02, 2010: Antisense Pharma's Trabedersen In Malignant Brain Tumors: Phase IIb Data Published In Neuro-Oncology
      • Oct 29, 2010: Novartis Drug Afinitor Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis.
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Brain Tumor, H2 2014
  • Number of Products under Development for Brain Tumor - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Brain Tumor - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014
  • Brain Tumor - Pipeline by Pfizer Inc., H2 2014
  • Brain Tumor - Pipeline by Bayer AG, H2 2014
  • Brain Tumor - Pipeline by Nanobiotix, H2 2014
  • Brain Tumor - Pipeline by Hutchison MediPharma Limited, H2 2014
  • Brain Tumor - Pipeline by Siena Biotech S.p.A., H2 2014
  • Brain Tumor - Pipeline by Oncovir, Inc., H2 2014
  • Brain Tumor - Pipeline by DEKK-TEC, Inc., H2 2014
  • Brain Tumor - Pipeline by SignPath Pharma Inc, H2 2014
  • Brain Tumor - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Brain Tumor Therapeutics - Recent Pipeline Updates, H2 2014
  • Brain Tumor - Dormant Projects, H2 2014
  • Brain Tumor - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Brain Tumor, H2 2014
  • Number of Products under Development for Brain Tumor - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top